Aliso Viejo-based ophthalmology company SpyGlass Pharma Inc. filed for an initial public offering last Friday.
The company, which is developing the world’s first IOL-mounted drug delivery platform capable of continuously releasing glaucoma medication to the eyes, plans to trade on the Nasdaq Global Market under the symbol “SGP”.
The size of the offering, or proposed stock price, hasn’t been determined yet. A $100 million placeholder value was given for the IPO.
SpyGlass recently signed a lease for a new two-story, 33,000-square-foot office building in Irvine.
The company hasn’t disclosed whether it is keeping its current space or if its headquarters are moving to Irvine. Company representatives declined to comment on the lease last week.
For more information, see the Jan. 26th print edition of the Business Journal.
